Caladrius Biosciences Company Profile (NASDAQ:CLBS)

About Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences logoCaladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CLBS
  • CUSIP: N/A
  • Web: www.caladrius.com
Average Prices:
  • 50 Day Moving Avg: $4.05
  • 200 Day Moving Avg: $4.51
  • 52 Week Range: $2.65 - $7.79
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.31
  • P/E Growth: -0.03
Profitability:
  • Net Margins: -84.10%
  • Return on Equity: -180.68%
  • Return on Assets: -51.96%
Debt:
  • Current Ratio: 4.84%
  • Quick Ratio: 4.84%
Misc:
  • Average Volume: 32,562 shs.
  • Beta: 1.62
 

Frequently Asked Questions for Caladrius Biosciences (NASDAQ:CLBS)

What is Caladrius Biosciences' stock symbol?

Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences, Inc. (NASDAQ:CLBS) posted its earnings results on Thursday, August, 10th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.96) by $0.08. Caladrius Biosciences had a negative return on equity of 180.68% and a negative net margin of 84.10%. View Caladrius Biosciences' Earnings History.

When will Caladrius Biosciences make its next earnings announcement?

Caladrius Biosciences is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Caladrius Biosciences.

Where is Caladrius Biosciences' stock going? Where will Caladrius Biosciences' stock price be in 2017?

2 equities research analysts have issued 12 month price targets for Caladrius Biosciences' shares. Their predictions range from $6.50 to $7.00. On average, they expect Caladrius Biosciences' share price to reach $6.75 in the next year. View Analyst Ratings for Caladrius Biosciences.

Who are some of Caladrius Biosciences' key competitors?

Who are Caladrius Biosciences' key executives?

Caladrius Biosciences' management team includes the folowing people:

  • David J. Mazzo Ph.D., Chief Executive Officer, Independent Director
  • Joseph Talamo, Chief Financial Officer, Senior Vice President
  • Douglas W. Losordo M.D., Chief Medical Officer
  • Gregory B. Brown M.D.,, Director
  • Richard J. Berman J.D., Independent Director
  • Drew Bernstein CPA.,, Independent Director
  • Martyn D. Greenacre, Independent Director
  • Steven Mark Klosk, Independent Director

Who owns Caladrius Biosciences stock?

Caladrius Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (0.00%). View Institutional Ownership Trends for Caladrius Biosciences.

Who bought Caladrius Biosciences stock? Who is buying Caladrius Biosciences stock?

Caladrius Biosciences' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for Caladrius Biosciences.

How do I buy Caladrius Biosciences stock?

Shares of Caladrius Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Caladrius Biosciences' stock price today?

One share of Caladrius Biosciences stock can currently be purchased for approximately $3.87.


MarketBeat Community Rating for Caladrius Biosciences (NASDAQ CLBS)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  262
MarketBeat's community ratings are surveys of what our community members think about Caladrius Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Caladrius Biosciences (NASDAQ:CLBS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.75 (74.42% upside)

Analysts' Ratings History for Caladrius Biosciences (NASDAQ:CLBS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/6/2017HC WainwrightReiterated RatingBuy$7.00LowView Rating Details
11/9/2016Chardan CapitalReiterated RatingBuy$6.50N/AView Rating Details
5/14/2016Maxim GroupReiterated RatingHoldN/AView Rating Details
4/30/2016Rodman & RenshawUpgradeBuyN/AView Rating Details
1/26/2016AegisReiterated RatingBuyN/AView Rating Details
9/24/2015WBB SecuritiesReiterated RatingBuy$7.00N/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Caladrius Biosciences (NASDAQ:CLBS)
Earnings by Quarter for Caladrius Biosciences (NASDAQ:CLBS)
Earnings History by Quarter for Caladrius Biosciences (NASDAQ CLBS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.79)N/AView Earnings Details
8/10/2017Q2 2017($0.96)($0.88)ViewN/AView Earnings Details
5/18/2017Q1 2017($0.72)($1.12)$9.50 million$7.92 millionViewN/AView Earnings Details
3/17/2017Q4 2016($0.80)($0.73)$6.30 million$10.18 millionViewN/AView Earnings Details
11/7/2016Q3($1.55)($1.09)$7.70 million$9.32 millionViewListenView Earnings Details
8/9/2016Q216($1.75)($1.33)$7.53 million$8.30 millionViewN/AView Earnings Details
3/15/2016Q4($0.28)($0.59)$7.67 million$7.60 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.30)($0.21)$6.00 million$5.89 millionViewN/AView Earnings Details
8/6/2015Q215($0.32)($0.31)$5.20 million$5.87 millionViewN/AView Earnings Details
10/30/2014Q3 2014($0.41)($0.44)$4.00 million$4.12 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.28)($0.38)$4.70 million$4.49 millionViewN/AView Earnings Details
11/14/2012Q312($0.05)($0.06)$3.50 million$4.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Caladrius Biosciences (NASDAQ:CLBS)
Current Year EPS Consensus Estimate: $-2.73 EPS
Next Year EPS Consensus Estimate: $-2.95 EPS

Dividends

Dividend History for Caladrius Biosciences (NASDAQ:CLBS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Caladrius Biosciences (NASDAQ:CLBS)
Insider Ownership Percentage: 13.10%
Institutional Ownership Percentage: 6.47%
Insider Trades by Quarter for Caladrius Biosciences (NASDAQ:CLBS)
Institutional Ownership by Quarter for Caladrius Biosciences (NASDAQ:CLBS)
Insider Trades by Quarter for Caladrius Biosciences (NASDAQ:CLBS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017Eric WeiDirectorSell6,575$4.77$31,362.75View SEC Filing  
2/6/2017Eric WeiDirectorSell8,425$4.61$38,839.25View SEC Filing  
7/1/2016Eric WeiDirectorSell87,500$0.60$52,500.00View SEC Filing  
6/24/2016Eric WeiDirectorSell22,698$0.55$12,483.90View SEC Filing  
8/17/2015David J MazzoCEOBuy20,000$1.40$28,000.00View SEC Filing  
8/11/2015Robert S VatersCFOBuy81,000$1.24$100,440.00View SEC Filing  
12/9/2014Steven S MyersDirectorBuy20,000$3.56$71,200.00View SEC Filing  
12/8/2014Rimasia Capital Partners ManagDirectorSell16,060$3.75$60,225.00View SEC Filing  
12/3/2014Rimasia Capital Partners ManagDirectorSell12,000$4.01$48,120.00View SEC Filing  
12/1/2014Steven S MyersDirectorBuy10,000$3.92$39,200.00View SEC Filing  
11/25/2014Steven M KloskDirectorBuy10,000$3.99$39,900.00View SEC Filing  
11/24/2014Andrew L PecoraInsiderBuy12,500$4.01$50,125.00View SEC Filing  
11/24/2014Steven S MyersDirectorBuy19,800$3.94$78,012.00View SEC Filing  
12/12/2013Richard BermanDirectorSell12,218$5.99$73,185.82View SEC Filing  
12/9/2013Rimasia Capital Partners Managmajor shareholderSell12,530$6.37$79,816.10View SEC Filing  
12/28/2012Richard J BermanDirectorSell149,306$0.59$88,090.54View SEC Filing  
9/18/2012Richard J BermanDirectorSell36,000$0.69$24,840.00View SEC Filing  
9/17/2012Rimasia Capital Partners ManagMajor ShareholderSell30,000$0.71$21,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Caladrius Biosciences (NASDAQ:CLBS)
Latest Headlines for Caladrius Biosciences (NASDAQ:CLBS)
Source:
DateHeadline
nasdaq.com logoWhy These 4 Biotech Stocks May Not Lose Momentum Soon - Nasdaq
www.nasdaq.com - September 11 at 5:55 PM
finance.yahoo.com logoWhy These 4 Biotech Stocks May Not Lose Momentum Soon
finance.yahoo.com - September 11 at 5:55 PM
finance.yahoo.com logoType 1 Diabetes May Soon Meet Its Match
finance.yahoo.com - September 8 at 5:40 PM
nasdaq.com logoCaladrius Biosciences to Participate at Upcoming September Conferences - Nasdaq
www.nasdaq.com - September 8 at 3:21 AM
finance.yahoo.com logoCaladrius Biosciences to Participate at Upcoming September Conferences
finance.yahoo.com - September 7 at 5:19 PM
americanbankingnews.com logoCaladrius Biosciences' (CLBS) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - September 6 at 3:56 PM
streetinsider.com logoCaladrius Biosciences (CLBS) Reports Enrollment of 70th Subject in Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 ... - StreetInsider.com
www.streetinsider.com - September 5 at 6:47 PM
finance.yahoo.com logoCaladrius Biosciences Announces Enrollment of the 70th Subject in the Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 Diabetes
finance.yahoo.com - September 5 at 6:47 PM
americanbankingnews.com logoCaladrius Biosciences, Inc. (CLBS) Upgraded at ValuEngine
www.americanbankingnews.com - September 3 at 6:32 PM
americanbankingnews.com logoCritical Analysis: Arbutus Biopharma Corp (ABUS) and Caladrius Biosciences (CLBS)
www.americanbankingnews.com - August 25 at 6:28 AM
americanbankingnews.com logoCaladrius Biosciences, Inc. (CLBS) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - August 15 at 6:08 PM
americanbankingnews.com logoCaladrius Biosciences, Inc. (CLBS) PT Set at $7.00 by HC Wainwright
www.americanbankingnews.com - August 13 at 3:32 PM
americanbankingnews.com logoCaladrius Biosciences, Inc. (CLBS) Posts Earnings Results, Beats Estimates By $0.08 EPS
www.americanbankingnews.com - August 11 at 12:24 PM
finance.yahoo.com logoInvestor Network: Caladrius Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - August 10 at 6:29 PM
finance.yahoo.com logoCaladrius Biosciences Reports 2017 Second Quarter Results
finance.yahoo.com - August 10 at 6:29 PM
globenewswire.com logoCaladrius Biosciences to Host 2017 Second Quarter Results ... - GlobeNewswire (press release)
globenewswire.com - August 3 at 11:50 PM
finance.yahoo.com logoCaladrius Biosciences to Host 2017 Second Quarter Results Conference Call on August 10, 2017 at 4:30 p.m. Eastern Time
finance.yahoo.com - August 3 at 6:48 PM
americanbankingnews.com logoCaladrius Biosciences, Inc. (CLBS) Set to Announce Earnings on Monday
www.americanbankingnews.com - July 31 at 8:15 AM
americanbankingnews.com logoZacks: Brokerages Expect Caladrius Biosciences, Inc. (NASDAQ:CLBS) to Post -$0.96 EPS
www.americanbankingnews.com - July 29 at 7:21 AM
americanbankingnews.com logoCaladrius Biosciences, Inc. (NASDAQ:CLBS) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - July 21 at 7:50 AM
streetinsider.com logoCaladrius Biosciences (CLBS) Says 50% of Subjects Have Been ... - StreetInsider.com
www.streetinsider.com - July 19 at 11:29 PM
americanbankingnews.com logoCaladrius Biosciences, Inc. (CLBS) Upgraded at Zacks Investment Research
www.americanbankingnews.com - July 19 at 9:50 PM
finance.yahoo.com logoCaladrius Biosciences Announces that 50% of Subjects Have Been Treated in the Phase 2 Clinical Trial of CLBS03 for Type 1 Diabetes
finance.yahoo.com - July 19 at 6:23 PM
finance.yahoo.com logoETFs with exposure to Caladrius Biosciences, Inc. : July 12, 2017
finance.yahoo.com - July 12 at 5:53 PM
americanbankingnews.com logo-$0.96 Earnings Per Share Expected for Caladrius Biosciences, Inc. (NASDAQ:CLBS) This Quarter
www.americanbankingnews.com - July 4 at 10:28 PM
nasdaq.com logoCaladrius Biosciences Joins Russell Microcap® Index - Nasdaq
www.nasdaq.com - June 26 at 5:00 PM
finance.yahoo.com logoCaladrius Biosciences Joins Russell Microcap® Index
finance.yahoo.com - June 26 at 5:00 PM
finance.yahoo.com logoInvetech and Caladrius Biosciences Receive 2017 Good Design Award® for Design of a Counterflow Centrifuge Device for use in the Development of Cell Therapies
finance.yahoo.com - June 14 at 5:09 PM
americanbankingnews.com logoValuEngine Upgrades Caladrius Biosciences Inc (CLBS) to Sell
www.americanbankingnews.com - June 10 at 11:44 PM
americanbankingnews.com logoCaladrius Biosciences Inc (CLBS) Short Interest Update
www.americanbankingnews.com - June 9 at 3:50 PM
americanbankingnews.com logoCaladrius Biosciences Inc (CLBS) Expected to Announce Earnings of -$0.96 Per Share
www.americanbankingnews.com - June 8 at 10:18 PM
seekingalpha.com logoCaladrius Biosciences (CLBS) Presents At 7th Annual LD Micro Invitational Conference - Slideshow
seekingalpha.com - June 7 at 7:09 PM
finance.yahoo.com logoETFs with exposure to Caladrius Biosciences, Inc. : June 2, 2017
finance.yahoo.com - June 2 at 5:49 PM
finance.yahoo.com logoCaladrius Biosciences to Participate at Upcoming June Conferences
finance.yahoo.com - June 1 at 4:56 PM
finance.yahoo.com logoETFs with exposure to Caladrius Biosciences, Inc. : May 23, 2017
finance.yahoo.com - May 23 at 12:48 PM
americanbankingnews.com logoZacks Investment Research Upgrades Caladrius Biosciences Inc (CLBS) to "Hold"
www.americanbankingnews.com - May 22 at 6:26 PM
finance.yahoo.com logoCaladrius Biosciences, Inc. :CLBS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 22, 2017
finance.yahoo.com - May 22 at 12:35 PM
americanbankingnews.com logoCaladrius Biosciences Inc (CLBS) PT Set at $7.00 by HC Wainwright
www.americanbankingnews.com - May 19 at 8:29 PM
finance.yahoo.com logoCaladrius Biosciences Closes the Sale of its Remaining Interest in PCT to Hitachi Chemical for $75 Million
finance.yahoo.com - May 18 at 4:17 PM
globenewswire.com logoCaladrius Biosciences Announces 2017 First Quarter Financial Results - GlobeNewswire (press release)
globenewswire.com - May 17 at 11:38 AM
americanbankingnews.com logoCaladrius Biosciences Inc (CLBS) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 17 at 12:52 AM
finance.yahoo.com logoCaladrius Biosciences Announces 2017 First Quarter Financial Results
finance.yahoo.com - May 15 at 6:30 PM
americanbankingnews.com logoCaladrius Biosciences Inc (CLBS) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 15 at 5:42 PM
americanbankingnews.com logoCaladrius Biosciences Inc (CLBS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 9 at 6:24 PM
finance.yahoo.com logoCaladrius Biosciences to Host 2017 First Quarter Financial Results Conference Call on May 18, 2017 at 5:00 p.m. Eastern Time
finance.yahoo.com - May 9 at 4:20 PM
americanbankingnews.com logoCaladrius Biosciences (CLBS) Receiving Somewhat Positive News Coverage, Study Finds
www.americanbankingnews.com - May 4 at 1:13 AM
americanbankingnews.com logoCaladrius Biosciences Inc (CLBS) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - May 3 at 8:02 PM
americanbankingnews.com logoCaladrius Biosciences Inc (CLBS) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 1 at 3:16 PM
globenewswire.com logoCaladrius Biosciences to Participate at Upcoming May Conferences - GlobeNewswire (press release)
globenewswire.com - May 1 at 8:39 AM
finance.yahoo.com logoCaladrius Biosciences to Participate at Upcoming May Conferences
finance.yahoo.com - May 1 at 8:39 AM

Social

Chart

Caladrius Biosciences (CLBS) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff